Clinical Trial Update: Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating chemoembolization with or without sorafenib for unresectable hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Unresectable Hepatocellular Carcinoma

Drugs mentioned

• Chemoembolization
• Sorafenib tosylate (sorafenib tosylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2023-02-17